» Articles » PMID: 24815347

Abnormal Plasma Clot Structure and Stability Distinguish Bleeding Risk in Patients with Severe Factor XI Deficiency

Overview
Publisher Elsevier
Specialty Hematology
Date 2014 May 13
PMID 24815347
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Factor XI (FXI) deficiency is a rare autosomal recessive disorder. Many patients with even very low FXI levels (< 20 IU dL(-1) ) are asymptomatic or exhibit only mild bleeding, whereas others experience severe bleeding, usually following trauma. Neither FXI antigen nor activity predicts the risk of bleeding in FXI-deficient patients.

Objectives: (i) Characterize the formation, structure and stability of plasma clots from patients with severe FXI deficiency and (ii) determine whether these assays can distinguish asymptomatic patients ('non-bleeders') from those with a history of bleeding ('bleeders').

Methods: Platelet-poor plasmas were prepared from 16 severe FXI-deficient patients who were divided into bleeders or non-bleeders, based on bleeding associated with at least two tooth extractions without prophylaxis. Clot formation was triggered by recalcification and addition of tissue factor and phospholipids in the absence or presence of tissue plasminogen activator and/or thrombomodulin. Clot formation and fibrinolysis were measured by turbidity and fibrin network structure by laser scanning confocal microscopy.

Results: Non-bleeders and bleeders had similarly low FXI levels, normal prothrombin times, normal levels of fibrinogen, factor VIII, von Willebrand factor and factor XIII, and normal platelet number and function. Compared with non-bleeders, bleeders exhibited lower fibrin network density and lower clot stability in the presence of tissue plasminogen activator. In the presence of thrombomodulin, seven of eight bleeders failed to form a clot, whereas only three of eight non-bleeders did not clot.

Conclusions: Plasma clot structure and stability assays distinguished non-bleeders from bleeders. These assays may reveal hemostatic mechanisms in FXI-deficient patients and have clinical utility for assessing the risk of bleeding.

Citing Articles

The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease.

Ali A, Becker R J Thromb Thrombolysis. 2024; 57(8):1283-1296.

PMID: 38662114 PMC: 11645312. DOI: 10.1007/s11239-024-02985-0.


Clot formation and fibrinolysis assays reveal functional differences among hemostatic agents in hemophilia A plasma.

Holle L, Pantazis J, Turecek P, Wolberg A Res Pract Thromb Haemost. 2024; 8(1):102337.

PMID: 38426025 PMC: 10901841. DOI: 10.1016/j.rpth.2024.102337.


Biology of factor XI.

Moellmer S, Puy C, McCarty O Blood. 2023; 143(15):1445-1454.

PMID: 37874916 PMC: 11033592. DOI: 10.1182/blood.2023020719.


Anticoagulation in the ICU: a future for contact pathway inhibition?.

Van Edom C, Gorog D, Vandenbriele C Intensive Care Med. 2023; 49(11):1388-1391.

PMID: 37522956 DOI: 10.1007/s00134-023-07172-y.


Protocol for the Investigation of Plasma and Whole Blood Clot Property of Fibrin Fiber Thickness Using Scanning Electron Microscopy.

Cai T, McCafferty C, Van Den Helm S, Letunica N, Attard C, Monagle P Methods Mol Biol. 2023; 2663:775-786.

PMID: 37204752 DOI: 10.1007/978-1-0716-3175-1_52.


References
1.
Ragni M, Sinha D, Seaman F, Lewis J, Spero J, Walsh P . Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds. Blood. 1985; 65(3):719-24. View

2.
Rugeri L, Quelin F, Chatard B, de Mazancourt P, Negrier C, Dargaud Y . Thrombin generation in patients with factor XI deficiency and clinical bleeding risk. Haemophilia. 2010; 16(5):771-7. DOI: 10.1111/j.1365-2516.2010.02246.x. View

3.
Allen G, Persson E, Campbell R, Ezban M, Hedner U, Wolberg A . A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol. 2007; 27(3):683-9. DOI: 10.1161/01.ATV.0000257204.82396.2b. View

4.
Machlus K, Colby E, Wu J, Koch G, Key N, Wolberg A . Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram. Thromb Haemost. 2009; 102(5):936-44. PMC: 2904819. DOI: 10.1160/TH09-03-0180. View

5.
Crosby J, Marzec U, Revenko A, Zhao C, Gao D, Matafonov A . Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol. 2013; 33(7):1670-8. PMC: 3717325. DOI: 10.1161/ATVBAHA.113.301282. View